WO2016013909A1 - Procédé de criblage d'agent thérapeutique pour un cancer à l'aide d'une interaction entre ikba et aurkc - Google Patents

Procédé de criblage d'agent thérapeutique pour un cancer à l'aide d'une interaction entre ikba et aurkc Download PDF

Info

Publication number
WO2016013909A1
WO2016013909A1 PCT/KR2015/007751 KR2015007751W WO2016013909A1 WO 2016013909 A1 WO2016013909 A1 WO 2016013909A1 KR 2015007751 W KR2015007751 W KR 2015007751W WO 2016013909 A1 WO2016013909 A1 WO 2016013909A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
protein
ikba
aurkc
fluorescent protein
Prior art date
Application number
PCT/KR2015/007751
Other languages
English (en)
Korean (ko)
Inventor
정영호
한은희
김남두
김현경
Original Assignee
한국기초과학지원연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국기초과학지원연구원 filed Critical 한국기초과학지원연구원
Publication of WO2016013909A1 publication Critical patent/WO2016013909A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Definitions

  • the present invention relates to a method for screening cancer therapeutic agents through the interaction of IkBa and AURKC. More particularly, the present invention relates to a binding inhibitor compound of ikBa and AURKC and a composition for preventing and treating cancer comprising the same as an active ingredient. .
  • IkBa (nuc lear factor of kappa light polypeptide gene enhancer in B eel I s inhibitor, alpha) protein is a type of control subunit that inhibits NF- ⁇ ⁇ activity.
  • IkBa binds to the nuclear position signal (NLS) site of NF-kB to mask the nuclear position signal so that NF-kB remains inactivated in the cytoplasm.
  • IkBa also prevents the NF—kB translation factor from binding to the DNA needed for NF-kB to function.
  • IkBa protein has been found to have IkBa protein mutations in some Hawkins lymphoma cells. This mutation inactivates IkBa, resulting in chronic activation of NF-kB. Lymphoma tumors have been reported to be directly associated with the development of malignant tumors (Cabannes E et al, Oncogene 18 (20): 3063770).
  • SerURe / threonine-protein kinase 13 (AURKC) protein is an enzyme encoded by the AUPKC gene (Bernard M et al., Genomi cs 53 (3): 40679). This gene encodes the aurora subfami ly of serine and threonine protein kinase.
  • the encoded protein is a chromosomal transport protein that complexes with Aurora B and the internal centrosome protein and can play a role in tissue microtubules with respect to centrosome and spindle function during mitosis. This gene is overexpressed in some cancer cell lines, indicating that it is involved in tumor signal transduction.
  • the growth, differentiation, and death of cells can be attributed to protein-protein, protein-nucleic acid. It is made by the interaction between high molecular materials. Out-of-cell signals pass through receptors on the cell membrane and pass through the cell's nucleus through several biochemical reactions in the cytoplasm, where they express specific genes. This intracellular delivery of these external signals is achieved by interactions between proteins at different levels. For example, growth factors or cytokines bind to the corresponding receptors on the cell surface, which induces clustering of the receptors. Ligand aggregation by these receptors causes the intracellular domains of the receptors to aggregate together, leading to interactions with various proteins involved in intracellular signaling.
  • This signaling system creates intermediate proteins that can deliver multiple levels of signal through protein kinase phosphorylation, protein phosphatase dephosphorylation, and so on, and eventually the signal is transferred to transcriptional activators.
  • Activated transcriptional promoters bind to DNA and interact with basic transcriptional apparatus such as RNA polymerase that synthesizes mRNA to activate specific genes. Therefore, these interactions control specific transcription, specifically in response to specific tissues, developmental processes and external stimuli.
  • the cause of the disorder is that abnormal interactions such as alteration, inhibition, and promotion between specific proteins are caused by invasion of foreign substances or genetic variation of internally active proteins. Therefore, the research that has been continued because the substance that can control this interaction can provide a method of treatment for the disease caused by it.
  • yeast two hybrids Y2H
  • fluorescence resonance energy transfer FRET
  • fluorescence resonance energy transfer FRET
  • recombination of split proteins biniolecular fluorescence com
  • Bi-FC recombination of split proteins
  • the inventors of the present invention have completed a cancer drug screening method using IkBa and AURKC based on the system for confirming the protein-protein interaction.
  • an object of the present invention is to provide a method for screening a cancer drug through IkBa and AURKC.
  • Another object of the present invention is to provide a compound screened through the cancer drug screening method.
  • Still another object of the present invention is to provide a composition for preventing and treating cancer, which comprises the screened compound as an active ingredient.
  • Another object of the present invention is to provide a use of the screened compound for the manufacture of a prophylactic and therapeutic agent for cancer.
  • Still another object of the present invention is to provide a method for preventing and treating cancer, wherein the screened compound is administered to an individual in need thereof in an effective amount.
  • the present invention provides a method for screening a cancer drug through IkBa and AURKC.
  • the present invention provides a compound screened through the cancer drug screening method.
  • the present invention provides a composition for preventing and treating cancer comprising the screened compound as an active ingredient.
  • (A) (i) expressing a fusion protein in which sequentially bound fusion proteins, a first marker, and IkBa, and a fusion protein in which a second marker, AURKC are sequentially coupled, Preparing a cell expressing a fusion protein to which a label, IkBa is sequentially coupled, mobile mothers, second markers, and AURKC are sequentially coupled to each other;
  • the present invention provides a method for screening a cancer drug, wherein the cancer drug candidate is identified as a cancer drug when it inhibits binding of IkBa protein and AURKC protein.
  • the present invention used intracellular localization of proteins generated by external stimulation or intrinsic signaling mechanisms.
  • a mobile parent whose position is moved by an external stimulus or an intrinsic signal transduction operation, a constituent in which the labeling material and the IkBa or AURKC which can be tracked are sequentially designed, and the labeling material and the AURKC or IkBa are A second construct was sequentially designed.
  • the first label and the second label should each contain one different IkBa and one AURKC.
  • the second component should be composed of the second marker, AURKC, and if the first component is the carrier, the first marker, and the AURKC, the second component is: It should consist of two markers, IkBa.
  • the present invention determines whether the first component and the second component bind to each other, and whether the first component and the second component interfere with the binding of the first component and the second component to the cancer therapeutic agent. If inhibition of the binding of the first component and the second component is determined as a cancer treatment.
  • Mobile hair in the present invention is a site that functions to move the crab 1 to a specific area in the cell.
  • movement to a specific region within a cell is caused by an external signal. It is possible to migrate haphazardly or intrinsically, and certain regions within the cell represent separate, discrete and identifiable elements present in the cell as intracellular structures.
  • the intracellular specific region may preferably be a membrane structure such as a cell membrane or a nuclear membrane or intracellular organelles such as endoplasmic reticulum, Golgi apparatus, mitochondria, lysosomes, and other intracellular specific regions.
  • the "mobile mothers" of the present invention is a protein kinase C (protein kinase C,
  • cPKC classic PKC; PKC-alpha, P C-beta, PKC— ga ⁇ a), nPKC (novel PKC; PKC-delta, PKC-epsilon, PKC-eta, PKOtheta) It is done.
  • the carriers of the present invention may use a variant of PKC, and the variant is more preferably a variant in which the intrinsic phosphorylation activity of PKC is eliminated in order to minimize disturbance caused by the intrinsic signaling mechanism.
  • the "first label” of the present invention is GFP (Green Fluorescent Protein)
  • Enhanced Green Fluorescent Protein EGFP
  • Red Fluorescent Protein RFP
  • Monomeric Red Fluorescent Protein mRFP
  • DsRed Red fluorescent protein
  • Cyan Fluorescent Protein CFP
  • Cyan Green Fluorescent Protein CGFP
  • YFP Yel low Fluorescent Protein
  • AzG AzG
  • HcR HcRed, Heteractis cr ispa red fluorescent protein
  • BFP Blue Fluorescent Protein
  • the "second label material” of the present invention is different from the one label material of the crab and GFP (Green
  • EGFP Fluorescent Protein
  • EGFP Enhanced Green Fluorescent Protein
  • RFP Red Fluorescent Protein
  • mRFP Monomeric Red Fluorescent Protein
  • DsRed Red fluorescent protein
  • CFP Cyan Fluorescent Protein
  • CFP Cyan Green Fluorescent Protein
  • YFP Yel low Fluorescent Protein
  • AzGCAzami Green HFP
  • HcRCHcRed Heteractis cr ispa red fluorescent protein
  • BFP Blue Fluorescent Protein
  • fusion protein refers to a protein or polypeptide having an amino acid sequence derived from two or more proteins. It may also comprise a linkage region of amino acids between amino acid moieties derived from.
  • the cell may be a cell of an animal, a plant, a yeast and a bacterium. Preferably, the cell may easily receive a first construct and a second construct, which are introduced from outside of the bacterium, and may be used for intracellular organelles such as cytoplasm and nucleus. Cells with distinct boundaries are preferred.
  • CHO-kl ATCC CCL-61, Cricetulus griseus, hamster, Chinese
  • HEK293 ATCCCRL-1573, Homo sapiens, human
  • HeLa ATCC CCL-2, Homo sapiens, human
  • SH-SY5Y ATCC CRL-2266, Homo sapiens, human
  • Swiss 3T3 ATCC CCL-92, Mus musculus, mouse
  • NIH / 3T3CATCC CRL-1658 Mus musculus, mouse
  • L-929 ATCC CCL-1, Mus musculus, mouse
  • Rat2 ATCCCRL-1764, Rat t us norvegicus, rat
  • RBL-2H3 ATCC CRL-2256, Rat t us norvegicus, rat
  • MDCK ATCC CCL-34, Can is familiar is).
  • the cells comprising the crab first construct and the second construct may be prepared by molecular biological methods known in the art.
  • the cells are transformed into individual expression vectors capable of expressing the first component and the second component or expression vectors capable of expressing both the first component and the second component, and then the system is expressed in the expression vector. Preferred is a method by which the first and second constructs are expressed.
  • each expression vector into cells can be carried out using transformation methods known in the art, such as calcium phosphate, calcium chloride, rubidium chloride, microprojectile bombardment, electroporation, Particle gun bombardment, silicon carbide whiskers, sonication, PEG-mediated fusion, microinjection, liposome mediation (1 iposome-mediated method), magnetic nanoparticle mediated method, and the like.
  • transformation methods known in the art such as calcium phosphate, calcium chloride, rubidium chloride, microprojectile bombardment, electroporation, Particle gun bombardment, silicon carbide whiskers, sonication, PEG-mediated fusion, microinjection, liposome mediation (1 iposome-mediated method), magnetic nanoparticle mediated method, and the like.
  • standard recombinant DNA and molecular cloning techniques used in the present invention are well known in the art and described in the following literature (Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory).
  • reaction refers to the proximal state between a particular ligand or compound, or a portion or fragment thereof, and a portion of the second molecule of interest. It may be non-covalent or covalent as a result of hydrogen-bonding, van der Waals interactions, electrostatic or hydrophobic interactions. 12-myri state 13-acetate,
  • Phorbol ester TPA (12-ot et r adecanoy lphor bo 1 -13-acetate), PDBu (phorbol 12, 13-dibutyrate), Adenosine triphosphate (ATP), tr idecanoic ac id, arachidonic acid, linoleic acid, DiC8 It is characterized in that selected from the group consisting of 130C937.
  • the "treatment of signal substance" of the present invention is characterized by treating PM Phorbol 12-myri state 13-acetate, Phorbol ester) at a concentration of 50nM to 5 ⁇ . More preferably luM.
  • concentration of the PMA is less than 50 nM, movement of the mobile mothers using the PKC is not difficult, and when the concentration of the PMA is greater than 5 uM, abnormal phenomena (eg, cell death signal disturbances, etc.) occur due to overtreatment of the chemical.
  • the "confirming the interaction” is to detect the distribution of the first label and the second label, for example, coverslips containing the cells to be identified.
  • It may be a method of fixing the coverslip to a perfusion chamber and mounting it on a material stage of a confocal laser fluorescence microscope (Cal Zeiss LSM710) and obtaining images of the component vectors before and after external stimulation.
  • the present invention provides a compound screened through the cancer drug screening method.
  • the compound of the present invention may be represented by the following formula (1). [Formula 1]
  • the compound of the present invention is characterized by inhibiting IkBa protein and AURKC protein binding.
  • the compound of the present invention is characterized by inhibiting the binding of the IkBa protein and AURKC protein to show cancer prevention and treatment effects.
  • the "cancer” of the present invention is gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosis, uterine cancer, cervical cancer head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, kidney Cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, hematologic cancer, lymphoma, psoriasis or fibroadenoma.
  • the present invention provides a composition for preventing and treating cancer, comprising an inhibitor of interaction between IkBa and AURKC as an active ingredient.
  • the inhibitor may be represented by the following formula (1).
  • composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. It may also be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions according to conventional methods. Suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceut i Cal Science, recently, Mack Publ i Shing Company, Easton PA.
  • Carrier excipients and diluents that may be included include lactose, dextrose, sucrose, sorbitol, manny, xylly, erythritol, maltitol, starch, acacia rubber, alginine. , Gelatin, Calcium Phosphate Shampoo, Cellulose, Methyl Cellulose, Microcrystalline Salose Polyvinyl Pyridone, Water, Methylhydroxy Benzoate, Propylhydroxyxbenzoate, Talc, Magnesium Stearate and Mineral oil and the like.
  • composition When formulating the composition, it is prepared using diluents or excipients such as layering agents, extenders, binders, wetting agents, disintegrating agents, and surfactants which are commonly used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. Such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose, lactose, It is prepared by mixing gelatin.
  • lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups.In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives are included. Can be.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent vegetable oils such as propylene glycol, polyethylene glycol olive oil, injectable esters such as ethyl oleate, and the like can be used.
  • witemsol macrogol, twenty-one, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • treatment refers to amelioration of a particular disease or disorder symptom, which may include treating such disorder, substantially preventing the development of the disorder, or improving the condition of the subject.
  • treatment refers to the full spectrum of treatment for a given disorder that afflicts a patient, which alleviates one or most of the symptoms resulting from that disorder, Treating certain disorders or preventing the development of a disorder.
  • the pharmaceutical composition of the present invention can be administered in parallel with a known compound having an effect of preventing and treating cancer or a known compound having an effect of inhibiting cancer metastasis.
  • the present invention provides a use of the inhibitor of the interaction between IkBa and AURKC for the manufacture of a prophylactic and therapeutic agent for cancer.
  • the present invention provides a method for preventing and treating cancer, comprising administering an effective inhibitor of the interaction between IkBa and AURKC to a subject in need thereof.
  • the inhibitor may be represented by the following formula (1).
  • H Inhibitors of interaction between IkBa and AURKC of the present invention can be administered in an effective amount via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular.
  • the term 'effective amount' refers to an amount that exhibits a therapeutic and prophylactic effect or a cancer metastasis inhibiting effect when administered to a patient
  • the term 'subject' includes an animal, preferably a mammal, particularly a human. It may be an animal, cells, tissues, organs and the like derived from the animal. The subject may be a patient (pat i ent) in need of treatment.
  • the interaction inhibitor between IkBa and AURKC of the present invention may be administered by itself or prepared and prepared in various formulations as described above, and is preferably administered until a desired effect, i.e., cancer prevention and treatment effect, is obtained.
  • the compounds of the present invention and their pharmaceutically acceptable salts can be administered by various routes according to methods known in the art. That is, orally or parenterally, such as oral, intramuscular, intravenous, intradermal, intraarterial, intramedullary, intradural, intramural, intranasal, intravaginal, intra rectal sublingual or subcutaneous, gastrointestinal tract, mucosa or respiratory tract. May be administered. Preferably it can be applied directly to the skin.
  • the compounds of the present invention and pharmaceutically acceptable salts thereof may be administered in a form that is bound to or encapsulated within a molecule that induces high affinity binding to the target cell or tissue.
  • Inhibitors of interactions between IkBa and AURKC of the present invention may be prepared using techniques known in the art, such as sterols (e.g. cholesterol), lipids (e.g. cationic lipids, bivalent or liposomes) or target cell specific binding agents (e.g. Ligands recognized by target cell specific receptors).
  • Suitable coupling or crosslinking agents can include, for example, Protein A, carbodiimide, N-succinimidyl-3- (2-pyridyldithio) propiotate (SPDP) and the like. These formulations are described in Remington's Pharmaceut i cal Science, 15th Edition, 1975, Mack Publ i Shing Company, East on, Pennsyl vani a).
  • the present invention provides a method for screening a cancer drug through the interaction of IkBa and AURKC. More specifically, the present invention provides a binding inhibitor compound of IkBa and AURKC and a composition for preventing and treating cancer comprising the same as an active ingredient.
  • the screening method of the present invention can be usefully used in that the cancer therapeutic agent can be easily screened depending on the inhibition of binding of IkBa and AURKC.
  • FIG. 1 is an overexpression of TMD-mRFP-IkBa (first construct) and EGFP-AURKC (second construct) in HEK293T cell line and analyzed by a method using cell imaging (Registration No. 10-0948767) (left) Panel; first component, middle panel; second component, right panel; first component + second component).
  • Figure 2 shows pTMD-mRFP-C3 p i asm i d (Crab 1 construct) and EGFP-AURKC (near 12 constructs)
  • TMD-mRFP-IkBa first construct
  • EGFP-AURKC second construct
  • 5A to 5D show gastric cancer cell lines AGS (A) and SNU638 b) and colorectal cancer cell lines.
  • FIG. 6 shows that TMD-mRFP-IkBa (first construct) and EGFP-AURKC (second construct) are overexpressed in HEK293T cells (Panel A) and CH0-K1 cell lines (Panel B) in the same manner and Compound 50 ⁇ M was treated for 3 hours. After that, 1 ⁇ ⁇ (external stimulus) was treated for 3 minutes to analyze the inhibition of binding of the two proteins in real time (left panel: 1st component, middle panel: 2nd component ⁇ right panel: 1st component + 1st) 2 components).
  • FIG. 7 shows a wound healing assay (A), a Transwell migration assay (B) and a soft agar assay by culturing breast cancer cell line MDA-MB-231 cells.
  • A wound healing assay
  • B Transwell migration assay
  • B soft agar assay by culturing breast cancer cell line MDA-MB-231 cells.
  • c soft agar assay by culturing breast cancer cell line MDA-MB-231 cells.
  • HEK293 ATCC CRL-1573, Homo sapiens, human
  • MDA-MB-231 ATCC HTB-26, Homo sapiens, human
  • A549 ATCC CC ⁇ 185 Homo sapiens, human
  • HepG2 ATCC HB -8065, HepG2, Homo sapiens, human
  • Culture conditions of animal cell lines used in the present invention was used for cell line culture method of ATCC (American Type Culture Collection), which is the organ of each cell line.
  • CH0-K1 was used for F-12 culture
  • HEK293 and MDA-MB-231 cell lines were used for DMEM culture
  • A549 and HepG2 cells were used for RPMI 1640, and other culture conditions were used in the same manner.
  • the common culture method of each cell is as follows (detailed culture conditions may vary depending on the purpose of the skilled person). Incubation at pH 7.4 with 25 niM HEPES, 10% FBS (fetal bovine serum, v / v), 100 units / ml penicillin, 100 ug / ml straptomycin In cell (F-12 and DMEM), each cell line was incubated in an incubator maintained at a temperature of 37 ° C., CO 2 partial pressure of 5%.
  • Intracellular gene introduction method used in the embodiment of the present invention used Fugene HD (Promega), one of the liposome-based methods commonly used, all conditions for gene introduction, such as the concentration of the gene is a manufacturer
  • Fugene HD Promega
  • the coverslips were placed in 6-plates, and the cells were cultured for one day, and then exchanged with 2 ml of fresh culture without penicillin, streptomycin, or FBS.
  • About one transgenic white sample was added to the culture medium without 0.1 ml of penicillin and streptomycin FBS, followed by complete mixing and addition of 3 Fugene HD reagents.
  • the solution was allowed to stand at room temperature for 15 minutes, then added to each well of a 6-plate containing the coverslips in which the cells were grown, incubated for 4 hours, and 200 ⁇ l of FBS was added for transformation for 18 hours. It was.
  • the first constituent includes a module (mobile mothers) that can move to the cell membrane when the protein evenly expressed in the cytoplasm has been treated with the signal amorphous substance, and can be analyzed using these microscopes.
  • the protein is labeled and bound, and finally consists of a fusion sequence to which the target substance can be bound.
  • the first construct was constructed using restriction enzymes EcoRI / Kpnl (IkBa) and EcoRI / Xinal (AURKC) with IkBa and AURKC in a TMD-mRFP-empty vector.
  • TMD—mRFP-empty vector is a vector comprising a Protein Kinase C mutant (TMD) represented by SEQ ID NO: 5 and mRFP represented by SEQ ID NO: 7.
  • IkBa is the template for pcDNA3.1-IkBa vector (NCBI Reference Sequence:
  • NM_020529.2 purchased from Mediscov Inc
  • PCR was performed using primers of SEQ ID NO: 1 and SEQ ID NO: 2.
  • AURKC performed PCR using a PPTB7-AURKC vector (GenBank: BC002363) as a template and primers of SEQ ID NO: 3 and SEQ ID NO: 4. Obtained after PCR amplification using primers Water was prepared by inserting into the EcoRI / Kpnl (IkBa) and EcoRI / Xmal (AURKC) positions of the pTMD-mRFP-C3 vector.
  • the second construct includes a label for analyzing the movement of a target substance having intrinsic properties of binding to a target substance bound to the first component.
  • Crab bicomponent uses green fluorescent protein (EGFP), a fluorescence that is different from the label contained in the first construct.
  • the second construct was constructed using restriction enzymes EcoRI / Kpnl (IkBa) and EcoRI / Xmal (AURKC) from IkBa and AURKC in an EFRP-C3 vector (clontech) of a previously registered patent (e.g. 10-1217718). .
  • IkBa is the template for the pcDNA3.1—IkBa vector (NCBI Reference Sequence:
  • AURKC was performed using a PPTB7-AUR C vector (GenBank: BC002363) as a template and using primers of SEQ ID NO: 3 and SEQ ID NO: 4. After PCR amplification using the primers, the obtained product was prepared by inserting into the EcoRI / Kpnl (IkBa) and EcoRI / Xnial (AURKC) positions of the pTMD-mRFP-C3 vector.
  • the confocal laser microscope uses a 488 nni Argon laser (EGFP) and a 543 nm HeNe laser (niRFP) to excite the fluorescent label, and the fluorescent signal generated from each fluorescent label is a band path filter BP505.
  • EGFP 488 nni Argon laser
  • niRFP 543 nm HeNe laser
  • the fluorescent signal generated from each fluorescent label is a band path filter BP505.
  • -530 EGFP
  • Long path filter LP560 or BP560-630 niRFP
  • the red fluorescence caused by the first component vector including the moving mothers (TMD) after the external stimulation using the confocal laser fluorescence microscope is transferred to the cell membrane.
  • the green fluorescence by the second material vector for the target material without the mobile hairs is distributed evenly in the cytoplasm as in stimulation.
  • a 12-element vector is an external stimulus
  • the migration of the second constituent to the cell membrane is necessarily based on the binding of the target substance to the target substance.
  • IkBa proteins regulated by TNF-a pha are known to be involved in various cellular signaling mechanisms in cells. Of particular interest among the various mechanisms is that they have a close relationship with provoking inflammation in response to various risk signals occurring in vivo.
  • the binding of AURKC protein interacting with IkBa was performed in real time using living cells.
  • the first and second constructs prepared above were transformed into HEK293T and CH0-K1 cell lines, and their fluorescence was confirmed at 0 and 3 minutes.
  • the first construct (TMD-mRFP-IkBa) was evenly distributed in the cell at 0 minutes, and then moved to the cell membrane after 3 minutes (left panel in Fig. 1).
  • EGFP-AURKC was also distributed evenly in the cell at 0 min and then moved to the cell membrane with the first construct after 3 min (panel in FIG. 1). This means that the first component and the second component are combined.
  • the first component is replaced by TMD-mFRP-AU KC and the second component is replaced by EGRP—IkBa.
  • HEK2953T and CH0-K1 cell lines were transformed and fluorescence was detected at 0 and 3 minutes.
  • the first construct (TMD-mRFP-AURKC) was evenly distributed in the cells at 0 minutes, and then moved to the cell membrane after 3 minutes (Fig. 3 is the left panel).
  • the two constructs (EGFP-IkBa) were also distributed evenly within the cell at 0 min and then migrated to the cell membrane with the first construct after 3 min ( Figure 3-middle panel). This means that the first component and the second component are combined.
  • the first and second compositions prepared above are prepared.
  • the cells were transformed into coverslips in which HEK293T and CH0-K1 cells grew. Afterwards, IkBa protein and AURKC protein binding inhibitor candidates were Treated during.
  • the coverslip is secured to the perfusion chamber, mounted on the stage of the confocal laser fluorescence microscope (Cal Zeiss LSM710), for component vectors before and after external stimulation ( ⁇ Phorbol ester). Image was acquired.
  • Figure 6 is an analysis of the binding inhibitory effect of the IkBa protein and AURKC protein of the compound TMD-mRFP-IkBa (first component) and EGFP-AURKC (component 2) in the same manner in HEK293T cells and CH0-K1 cell line Overexpressed and treated 50 ⁇ M of the compound for 3 hours. Thereafter, 1 ⁇ of ⁇ (external stimulus) was treated for 3 minutes to analyze the inhibition of binding of both proteins in real time. It was confirmed that the above compound did not bind the IkBa protein and the AURKC protein, and the red fluorescence reflecting the moving mothers and IkBa moved to the cell membrane, but the green fluorescence reflecting the AURKC protein was located in the cytoplasm. Therefore, it can be seen that the compound represented by Chemical Formula 1 can be used as an inhibitor that inhibits the binding of IkBa and AURKC.
  • Cytotoxicity of the compounds used in the examples of the invention was used a commonly used CCK8 kit (Dojindo Molecular Technologies) and all conditions were performed according to the manufacturer's instructions. More specifically, cells were cultured in 96-plate for one day, 10, 50, and 100 ⁇ were treated with the compound and incubated for 24 and 48 hours, followed by 10 ⁇ l of CCK8 solution, and the absorbance was measured at 450 nm for one hour.
  • gastric cancer cell lines AGS and SNU638 (FIG. 5, B) and colon cancer cell lines HCT116 and SW620 (C), uterine cancer cell line Hela (MA) ⁇ breast cancer cell line MDA—MB-231 (F), as shown in FIG. Cytotoxicity was measured in lung cancer cell line A549 and HepG2 cell line, and these cancer cells were inhibited by compounds that inhibit the interaction of IkBa and AURKC. Death increased.
  • the cancer cell migration assay was performed using a breast cancer cell line MDA—MB-231 cultured in DMEM containing 10% FBS at 37 ° C. 5% CO 2 conditions (FIG. 7A). Cells are incubated for 24 hours in 24 well tissue culture plates (2 ⁇ 10 5 cells). Thereafter, the wound is slowly cut across the center of the well using a lnil pipette tip without changing medium. At this time, use the tip upright with the bottom of the well, cut the wound in one direction, and march twice with medium to remove the fallen cells, and then supplement the new medium. In addition, 25 ⁇ M of compounds inhibiting the interaction of the plate group IkBa with AURKC were treated and incubated for 48 hours. This is followed by two marches with IX PBS followed by fixation with 3.7% paraformaldehyde for 30 minutes. The fixed cells were stained for 30 minutes by dissolving 1% crystal vial in 2% ethane and observed using a microscope.
  • the control group ( ⁇ ) without treatment of the compound that inhibits the interaction of IkBa and AURKC in the breast cancer cell line was narrower than that of the treatment with the compound (25 ⁇ ). Confirmed.
  • the cells grew on the wounded portion with the tip to fill the space, but when the compound was treated, the cells did not grow on the wounded portion and the space remained. That is, it was confirmed that the compound which inhibits the interaction of IkBa and AURKC inhibits the proliferation of cells.
  • the transwell migration assay used a breast cancer cell line MDA-MB-231 incubated with 1 FBS of DMEM (FIG. 7B).
  • FBS 1 FBS of DMEM
  • To prepare the transwell 0.5% FBS and 2.6 ⁇ 1 DMEM were placed in the lower part of the 24 well, and 8 well sized transwell was added. Then, cells (1 ⁇ 10 5 cells) were added to the prepared transwells. Then, ⁇ and 25 ⁇ were added to the compounds that inhibit the interaction between IkBa and AURKC, and the cells were incubated for 2 hours and 30 minutes at 37 ° C, 5% C0 2 , to move down the filter fitted with the cells. It was.
  • cancer cell proliferation was inhibited by a compound that inhibits the interaction between IkB a and AURKC as in ⁇ 7-1>.
  • the colony morphology was analyzed by culturing the breast cancer cell line MDA-MB—231 in agar medium prepared using agarose by a Sot agar assay (FIG. 7). First, 4% agar was dissolved and kept warm in a 56 ° C constant temperature bath, and 10% FBS DMEM was kept at 37 ° C. In order to make a lower layer of agar medium to culture the cells, DMEM 5 [ii l containing 0.75% agar and 10% FBS was placed in a 60 mm culture dish and waited until it solidified. 10% including 0.36% agar to make the next upstairs
  • the present invention relates to a method for screening a cancer therapeutic agent through the interaction of IkBa and AURKC. More specifically, IkBa and AURKC binding inhibitor compound and the active ingredient It relates to a composition for preventing and treating cancer.
  • the present invention is effective in that cancer therapeutic agents can be screened at the molecular level and the action of the therapeutic agents can be known through intermolecular interactions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé pour cribler un agent thérapeutique pour un cancer à l'aide d'une interaction entre IkBa et AURKC et, plus spécifiquement, un composé d'inhibiteur de liaison IkBa et AURKC, et une composition permettant la prévention et le traitement de cancer le contenant comme principe actif. La présente invention est efficace en ce qu'un agent thérapeutique pour un cancer peut être criblé à un niveau moléculaire, et l'action de l'agent thérapeutique peut être identifiée à l'aide d'une interaction moléculaire.
PCT/KR2015/007751 2014-07-24 2015-07-24 Procédé de criblage d'agent thérapeutique pour un cancer à l'aide d'une interaction entre ikba et aurkc WO2016013909A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0094260 2014-07-24
KR20140094260 2014-07-24

Publications (1)

Publication Number Publication Date
WO2016013909A1 true WO2016013909A1 (fr) 2016-01-28

Family

ID=55163364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/007751 WO2016013909A1 (fr) 2014-07-24 2015-07-24 Procédé de criblage d'agent thérapeutique pour un cancer à l'aide d'une interaction entre ikba et aurkc

Country Status (2)

Country Link
KR (1) KR101738680B1 (fr)
WO (1) WO2016013909A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070048660A (ko) * 2004-07-20 2007-05-09 씨지케이 주식회사 물질의 상호작용 탐색 시스템
KR100948767B1 (ko) * 2008-11-12 2010-03-23 한국기초과학지원연구원 생체 고분자 물질의 상호작용 검출 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070048660A (ko) * 2004-07-20 2007-05-09 씨지케이 주식회사 물질의 상호작용 탐색 시스템
KR100948767B1 (ko) * 2008-11-12 2010-03-23 한국기초과학지원연구원 생체 고분자 물질의 상호작용 검출 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGQVIST, S. ET AL.: "The IkBa/NF-kB complex has two hot spots, one at either end of the interface", PROTEIN SCIENCE, vol. 17, 2008, pages 2051 - 2058 *
DATABASE PubChem 4 June 2005 (2005-06-04), Database accession no. 654580 *
KATSHA, A. ET AL.: "Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia", GASTROENTEROLOGY, vol. 145, no. 6, 2013, pages 1312 - 1322 and 1322.e1-1322.e8 *

Also Published As

Publication number Publication date
KR101738680B1 (ko) 2017-05-22
KR20160012957A (ko) 2016-02-03

Similar Documents

Publication Publication Date Title
US20120149651A1 (en) Caveolin peptides and their use as therapeutics
US20200038471A1 (en) Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
Dráberová et al. Differential expression of human γ‐tubulin isotypes during neuronal development and oxidative stress points to a γ‐tubulin‐2 prosurvival function
US8173360B2 (en) Cell death inhibitor
Lu et al. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3
CN111658644B (zh) 一种小分子stat3抑制剂wz-2-033及其在制备治疗乳腺癌和胃癌药物中的应用
Pang et al. Sodium cantharidate induces Apoptosis in breast cancer cells by regulating energy metabolism via the protein phosphatase 5-p53 axis
EP3605102B1 (fr) Utilisation d'une composition comprenant un proteine aimp2-dx2 pour le diagnostic du cancer du poumon
EP2754451A1 (fr) Utilisation d'ache comme nucléase
CN111484492B (zh) 一种取代吡啶并咪唑类化合物及其在制备治疗恶性肿瘤疾病药物中的应用
WO2008046107A9 (fr) Nouveaux inhibiteurs de kinase egfr ciblant l'interface de dimère à activation asymétrique
CN109627289B (zh) 一种具有抗肿瘤活性的bh3多肽类似物
CN110960677B (zh) Sage1抑制剂在制备药物或试剂盒中的用途
CN113730409B (zh) 奎纳克林在制备治疗肺纤维化药物中的应用
WO2016013909A1 (fr) Procédé de criblage d'agent thérapeutique pour un cancer à l'aide d'une interaction entre ikba et aurkc
Ren et al. SIPAR negatively regulates STAT3 signaling and inhibits progression of melanoma
KR101749670B1 (ko) IkBα 및 RPS6KA2의 상호작용을 통한 암 치료제 스크리닝 방법
CN115925881B (zh) 一种抑制set蛋白核质穿梭的多肽及其应用
CN109453384A (zh) Nod1在制备抑制肿瘤src信号通路的产品中的应用
CN115708821B (zh) 一种海洋真菌来源化合物在制备抗肿瘤血管生成的药物中的应用
US20090111733A1 (en) Par-4 related methods and compositions
KR101704772B1 (ko) IkBα와 RPS6KA2의 상호작용 저해제를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
US20150174191A1 (en) Pharmaceutical composition for treating hyperproliferative diseases
CN116135873A (zh) 试剂盒、靶向p53的多肽及其在制备用于治疗癌症的药物中的应用
US20100035825A1 (en) Treatment Of Disease By Inducing Cell Apoptosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824295

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15824295

Country of ref document: EP

Kind code of ref document: A1